Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine
Authors:
- 1 February 2010
- journal article
- research article
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 7 (2) , 116-122
Abstract
The novel influenza A (H1N1) 2009 virus has emerged to cause the first pandemic of the twenty-first century. Disease outbreaks caused by the influenza A (H1N1) virus have prompted concerns about the potential for a pandemic and have driven the development of vaccines against this subtype of influenza A. In this study, we developed a monovalent influenza A (H1N1) split vaccine and evaluated its effects in BALB/c mice. Mice were immunized subcutaneously with 2 doses of the vaccine containing hemagglutinin (HA) alone or HA plus an aluminum hydroxide (Al(OH)3) adjuvant. Immunization with varying doses of HA (3.75, 7.5, 15, 30, 45 or 60 µg) was performed to induce the production of neutralizing antibodies. The vaccine elicited strong hemagglutination inhibition (HI) and microneutralization, and addition of the adjuvant augmented the antibody response. A preliminary safety evaluation showed that the vaccine was not toxic at large doses (0.5 ml containing 60 µg HA+600 µg Al(OH)3 or 60 µg HA). Moreover, the vaccine was found to be safe at a dose of 120 µg HA+1200 µg Al(OH)3 or 120 µg HA in 1.0 ml in rats. In conclusion, the present study provides support for the clinical evaluation of influenza A (H1N1) vaccination as a public health intervention to mitigate a possible pandemic. Additionally, our findings support the further evaluation of the vaccine used in this study in primates or humans.Keywords
This publication has 32 references indexed in Scilit:
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Safety and Immunogenicity of Multiple and Higher Doses of an Inactivated Influenza A/H5N1 VaccineThe Journal of Infectious Diseases, 2009
- Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adultsVaccine, 2009
- Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in HumansNew England Journal of Medicine, 2009
- Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccineProceedings of the National Academy of Sciences, 2009
- Animal models for the study of influenza pathogenesis and therapyAntiviral Research, 2009
- A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccineVaccine, 2009
- A multi-valent vaccine approach that elicits broad immunity within an influenza subtypeVaccine, 2009
- Cross-clade protective immunity of H5N1 influenza vaccines in a mouse modelVaccine, 2008
- Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccinesVaccine, 2008